| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 3.03 | 3.26 |
| Gross Profit | 1.51 | 1.58 |
| Pretax Income | -0.09 | -0.38 |
| Net Income | -0.09 | -0.38 |
| Diluted EPS | -0.00 | -0.00 |
- Net Income YoY
- +75.7%
Key highlights
- Revenue declined to $3.03 million from $3.26 million in the prior year period
- Net loss narrowed significantly by 75.7% year-over-year to $0.09 million
- Company recorded a $0.5 million gain resulting from a legal settlement
- Generated positive cash flow from operations of $0.18 million during the quarter
- Nine-month net loss widened to $1.5 million compared to $0.8 million in 2025
How the Period Went
CV Sciences reported a revenue decrease for the third quarter of 2026, with top-line figures reaching $3.03 million compared to $3.26 million in the same period last year. This decline reflects ongoing challenges in product sales volumes within the competitive wellness market. However, the company demonstrated a notable reduction in its bottom-line deficit. The net loss for the quarter narrowed to $0.09 million, representing a 75.7% improvement over the $0.38 million net loss reported in the third quarter of 2025. This move toward break-even was primarily influenced by non-operating gains rather than core organic sales growth.
Margins and Profitability
Gross profit for the quarter stood at $1.51 million, down from $1.58 million in the prior year, essentially tracking the overall revenue decline. Despite the lower gross intake, the company's profitability profile was bolstered by a $0.5 million gain recognized from a legal settlement. This one-time item was critical in offsetting operational expenses during the three-month period. Furthermore, CV Sciences achieved a positive milestone in liquidity by generating $0.18 million in cash flow from operations. This quarterly cash generation contrasts with the wider $1.5 million net loss recorded over the full nine-month period ending September 30, 2026, which was impacted by debt conversion losses.
Business Overview
CV Sciences, Inc. operates as a consumer wellness company specializing in hemp-derived cannabidiol products. The company is best known for its flagship brand, PlusCBD, which is distributed across various retail channels including health food stores and e-commerce platforms. Its product portfolio encompasses a range of delivery formats such as oils, capsules, gummies, and topicals. The business focuses on the high-quality, science-backed segment of the hemp industry, targeting consumers seeking alternative wellness solutions for stress, sleep, and pain management. The company maintains a dual focus on its consumer product division and the development of plant-based prescription drug candidates.
Industry Landscape
The hemp-derived CBD industry continues to face a complex landscape characterized by intense competition and a lack of clear federal regulatory frameworks in the United States. Many peers in the cannabinoid space have reported similar revenue pressures as the market remains oversaturated with brands vying for limited retail shelf space. Changes in consumer spending habits and the rise of alternative hemp-derived cannabinoids have further fragmented demand. Companies in this sector are increasingly focusing on cost containment and operational efficiency to navigate these headwinds while waiting for potential legislative clarity regarding the regulation of CBD as a dietary supplement.
SEC filing by CV Sciences, Inc. announcing financial results for the quarter ended September 30, 2026.
Track CV Sciences, Inc. live
Get the next CV Sciences, Inc. SEC filing seconds after it lands.



